Highly active antiretroviral therapy is effective in reducing viral load and increasing survival in HIV-1-infected patients. It consists of two nucleoside reverse transcriptase inhibitors and a protease inhibitor or two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor. The efficacy of Highly active anti-retroviral therapy (HAART) is however compromised by adverse events such as lipodystrophy in patients on long-term HAART. This study was carried out in 265 HIV-1 seropositive patients treated with HAART for 6 months and longer, in order to correlate patients’ age, gender, CD4 counts, WHO stage at initiation of HAART, duration and type of anti-retroviral therapy with development of lipodystrophy. A longer duration of therapy was found to be significantly associated with the development of lipodystrophy with 19 patients (24.7%), 73 patients (60.8%) (OR 2.06; CI 1.21 to 3.51, p value 0.004) and 39 patients (67.2%) (OR 2.34; CI 1.21 to 1.46, p value 0.006) having lipodystrophy at 6 to 18, 18 to 36 and 36 to 72 months of treatment, respectively. The odds of lipodystrophy after HAART for 18 to 36 months and 36 to 72 months was 4.14 (p < 0.0001) and 6.179 (p < 0.0001) times, respectively, higher than after HAART for 6 to 18 months. There was no association between age, gender, CD4 counts, WHO stage and the development of lipodystrophy.
Key words: Lipodystrophy, immune reconstitution, protease inhibitors, WHO clinical stage, duration of highly active anti-retroviral therapy (HAART).
Copyright © 2021 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0